BIOAGE LABS, INC. Capital Expenditures
BIOAGE LABS, INC. (BIOA) reported Capital Expenditures of $354.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $328.00K, a 106.29% increase year-over-year.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $26.00K, a 93.90% decline year-over-year.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $112.00K, a 330.77% increase year-over-year.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $22.00K, a 92.79% decline year-over-year.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $719.00K, a 96.45% increase from fiscal 2024.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $366.00K, a 120.48% increase from fiscal 2023.
- BIOAGE LABS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $166.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $354.00K 10-Q · filed 2026-08-05 | $466.00K derived: sum of 3 quarters · filed 2026-08-05 | $488.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-08 | $138.00K derived: sum of 2 quarters · filed 2026-05-08 | $160.00K derived: sum of 3 quarters · filed 2026-05-08 | $319.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $134.00K derived: sum of 2 quarters · filed 2026-03-24 | $293.00K derived: sum of 3 quarters · filed 2026-08-05 | $719.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $181.00K derived: sum of 2 quarters · filed 2026-08-05 | $607.00K 10-Q · filed 2025-11-06 | $633.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $585.00K 10-Q · filed 2026-08-05 | $611.00K derived: sum of 3 quarters · filed 2026-08-05 | $916.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $426.00K 10-Q · filed 2026-05-08 | $452.00K derived: sum of 2 quarters · filed 2026-05-08 | $757.00K derived: sum of 3 quarters · filed 2026-05-08 | $792.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $331.00K derived: sum of 2 quarters · filed 2026-03-24 | $366.00K derived: sum of 3 quarters · filed 2026-03-24 | $366.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $340.00K derived: sum of 2 quarters · filed 2025-11-06 | $340.00K 10-Q · filed 2025-11-06 | $340.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $35.00K 10-Q · filed 2025-08-06 | $35.00K derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $166.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $166.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |